RU2019107667A3 - - Google Patents

Download PDF

Info

Publication number
RU2019107667A3
RU2019107667A3 RU2019107667A RU2019107667A RU2019107667A3 RU 2019107667 A3 RU2019107667 A3 RU 2019107667A3 RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A RU2019107667 A RU 2019107667A RU 2019107667 A3 RU2019107667 A3 RU 2019107667A3
Authority
RU
Russia
Application number
RU2019107667A
Other languages
Russian (ru)
Other versions
RU2019107667A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2019107667A publication Critical patent/RU2019107667A/ru
Publication of RU2019107667A3 publication Critical patent/RU2019107667A3/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2019107667A 2016-10-05 2017-10-03 Спироциклические соединения RU2019107667A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404668P 2016-10-05 2016-10-05
US62/404,668 2016-10-05
PCT/US2017/054865 WO2018067512A1 (en) 2016-10-05 2017-10-03 Spirocyclic compounds

Publications (2)

Publication Number Publication Date
RU2019107667A RU2019107667A (ru) 2020-11-06
RU2019107667A3 true RU2019107667A3 (https=) 2021-01-27

Family

ID=61831517

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019107667A RU2019107667A (ru) 2016-10-05 2017-10-03 Спироциклические соединения

Country Status (13)

Country Link
US (2) US10934304B2 (https=)
EP (1) EP3523306A4 (https=)
JP (2) JP6949952B2 (https=)
KR (1) KR20190075931A (https=)
CN (1) CN109890827A (https=)
AU (1) AU2017339890A1 (https=)
BR (1) BR112019005305A2 (https=)
CA (1) CA3037064A1 (https=)
IL (1) IL265752A (https=)
MX (1) MX2019003938A (https=)
RU (1) RU2019107667A (https=)
TW (1) TW201817732A (https=)
WO (1) WO2018067512A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
HUE049481T2 (hu) 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
IL281212B2 (en) * 2018-09-07 2023-12-01 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) * 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN110922421B (zh) * 2019-12-17 2023-05-05 安徽英特美科技有限公司 一种n-甲基-1,2,5,6-四氢吡啶-4-硼酸频哪醇酯的合成方法
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含fgfr抑制劑及nectin-4靶向劑之組合療法
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2025096858A1 (en) * 2023-10-31 2025-05-08 C4 Therapeutics, Inc. Compounds for the degradation of mutant braf

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3305776T (lt) * 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais
HRP20110892T1 (hr) * 2005-12-13 2011-12-31 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
WO2008063609A2 (en) 2006-11-17 2008-05-29 Polyera Corporation Diimide-based semiconductor materials and methods of preparing and using the same
WO2008156739A1 (en) * 2007-06-18 2008-12-24 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
WO2011071860A2 (en) 2009-12-07 2011-06-16 Alnylam Pharmaceuticals, Inc. Compositions for nucleic acid delivery
ES2609579T3 (es) * 2011-08-29 2017-04-21 VIIV Healthcare UK (No.5) Limited Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH
CN103130775B (zh) 2011-11-22 2015-09-30 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的吲哚满酮衍生物
US8987264B2 (en) * 2012-11-09 2015-03-24 Bristol-Myers Squibb Company 1,3,5-triazine derivatives of spiro bicyclic oxalamide-compounds for treatment of hepatitis C
KR102243637B1 (ko) 2013-03-14 2021-04-26 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 진통 화합물
WO2016106009A1 (en) 2014-12-22 2016-06-30 Eli Lilly And Company Erk inhibitors
CN105732636B (zh) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
HUE049481T2 (hu) 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek

Also Published As

Publication number Publication date
CN109890827A (zh) 2019-06-14
JP6949952B2 (ja) 2021-10-13
US10934304B2 (en) 2021-03-02
BR112019005305A2 (pt) 2019-07-02
JP2019534261A (ja) 2019-11-28
WO2018067512A1 (en) 2018-04-12
TW201817732A (zh) 2018-05-16
AU2017339890A1 (en) 2019-04-11
MX2019003938A (es) 2019-06-10
US20210115058A1 (en) 2021-04-22
CA3037064A1 (en) 2018-04-12
RU2019107667A (ru) 2020-11-06
KR20190075931A (ko) 2019-07-01
WO2018067512A8 (en) 2018-11-01
US20200207776A1 (en) 2020-07-02
EP3523306A1 (en) 2019-08-14
NZ751398A (en) 2021-03-26
JP2021193138A (ja) 2021-12-23
EP3523306A4 (en) 2020-05-06
IL265752A (en) 2019-06-30

Similar Documents

Publication Publication Date Title
BR112019001695A2 (https=)
RU2019107667A3 (https=)
BR122021013712A2 (https=)
BR112019002665A2 (https=)
BR112019001429A2 (https=)
BR112019009192A2 (https=)
BR112018004682A2 (https=)
BR112017026947A2 (https=)
BR112019009269A2 (https=)
BR112019003108A2 (https=)
BR102016025845A2 (https=)
BR202016025584U2 (https=)
BR202016018234U2 (https=)
CN303536234S (https=)
CN303537326S (https=)
CN303536106S (https=)
CN303536112S (https=)
CN303536125S (https=)
CN303536132S (https=)
CN303536205S (https=)
CN303536208S (https=)
CN303536213S (https=)
CN303536220S (https=)
CN303536232S (https=)
CN303537690S (https=)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20220110